[Duration of the after-control of the tuberculous patients following the termination of the treatment].
D000293:Adolescent; D000328:Adult; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D003523:Cycloserine / Q000627:therapeutic use; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000627:therapeutic use; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D013882:Thiosemicarbazones / Q000627:therapeutic use; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014756:Viomycin / Q000627:therapeutic use
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D013882:Thiosemicarbazones; D011718:Pyrazinamide; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin; D014756:Viomycin
Dauer der Nachkontrolle von Tuberkulosekranken nach Abschluss der Behandlung.